Browse MR1

Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass membrane protein; Extracellular side. Endoplasmic reticulum.; SUBCELLULAR LOCATION: Isoform 4: Secreted.; SUBCELLULAR LOCATION: Isoform 3: Cell membrane Single-pass type I membrane protein Endoplasmic reticulum membrane Note=The larger proportion remains in the ER in an immature state. The subset that reach cell surface does it through a B2M-independent pathway.
Domain PF07654 Immunoglobulin C1-set domain
PF00129 Class I Histocompatibility antigen
Function

Antigen-presenting molecule specialized in presenting microbial vitamin B metabolites. Involved in the development and expansion of a small population of T-cells expressing an invariant T-cell receptor alpha chain called mucosal-associated invariant T-cells (MAIT). MAIT lymphocytes are preferentially located in the gut lamina propria and therefore may be involved in monitoring commensal flora or serve as a distress signal. Expression and MAIT cell recognition seem to be ligand-dependent.

> Gene Ontology
 
Biological Process GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0019882 antigen processing and presentation
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032620 interleukin-17 production
GO:0042742 defense response to bacterium
GO:0048002 antigen processing and presentation of peptide antigen
GO:0050829 defense response to Gram-negative bacterium
GO:0098542 defense response to other organism
Molecular Function GO:0003823 antigen binding
GO:0032393 MHC class I receptor activity
Cellular Component GO:0042611 MHC protein complex
GO:0042612 MHC class I protein complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29668066colon adenocarcinomaPromote immunity (T&NK cell function); essential for immunotherapyAccordingly, MAIT cells are capable of lysing MR1-expressing cells infected with a variety of pathogenic bacteria in in vitro settings and may also mount cytotoxic responses during microbial infections in vivo.
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4940.142
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1610.902
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7460.38
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1280.598
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2490.862
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0240.989
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0310.941
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2760.854
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2580.887
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3390.83
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.690.775
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.020.837
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMR1
Namemajor histocompatibility complex, class I-related
Aliases HLALS; major histocompatibility complex, class I-like sequence; MHC class I-like antigen MR-1; MHC class-I r ......
Chromosomal Location1q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MR1.
ID Name Drug Type Targets #Targets
DB00098Antithymocyte immunoglobulin (rabbit)BiotechCD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR19